Evaluation of the PGAxBSA Composite Tool in Patients with Moderate-to-Severe Plaque Psoriasis

Kristina Callis Duffin; J Mark Jackson; Joana Goncalves; Eugenia Levi; Jerry Bagel

doi:10.25251/skin.1.supp.13

Kristina Callis Duffin
J Mark Jackson
Joana Goncalves
Eugenia Levi
Jerry Bagel

Keywords

psoriasis, severity index, PASI

Abstract

Abstract Not Available

Disclosure: Study supported by Celgene.

Poster PDF

Published

Oct 27, 2017

DOI https://doi.org/10.25251/skin.1.supp.13

How to Cite

Callis Duffin, K., Jackson, J. M., Goncalves, J., Levi, E., & Bagel, J. (2017). Evaluation of the PGAxBSA Composite Tool in Patients with Moderate-to-Severe Plaque Psoriasis. SKIN The Journal of Cutaneous Medicine, 1(3.1), s14. https://doi.org/10.25251/skin.1.supp.13

Issue

Vol. 1 (2017): Supplemental Issue: Scientific Posters Presented at 2017 Fall Clinical Dermatology Conference®-Las Vegas

Section

Poster Presentations from FC23 Dermatology Conference®: Psoriasis

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by the following user license:

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

Jerry Bagel, April W. Armstrong, Richard B. Warren, Kim A. Papp, Diamant Thaçi, Alan Menter, Jennifer Cather, Matthias Augustin, Lauren Hippeli, Carolin Daamen, Christopher EM Griffiths, Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: 52-week efficacy by prior treatment in the phase 3 POETYK PSO-1 trial , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference®
Lawrence Green, Jerry Bagel, George Han, Abby Jacobson, Martha Sikes, Halobetasol Propionate 0.01% Lotion for Plaque Psoriasis: Epidermal Permeation, Efficacy, and Safety , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference®
Neil Korman, Kim Papp, Jerry Bagel, Peter Foley, Akimichi Morita, Subhashis Banerjee, Elizabeth Colston, Tao Wang, John Throup, Diamant Thaci, Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Versus Placebo and Apremilast in Moderate to Severe Plaque Psoriasis: Onset of Action in the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)
April W. Armstrong, Mark Lebwohl, Jerry Bagel, Todd Schlesinger, Subhashis Banerjee, Renata M. Kisa, Thomas Scharnitz, Kim Hoyt, Bruce Strober, Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: efficacy by baseline body surface area (BSA) involvement and baseline Psoriasis Area and Severity Index (PASI) , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference®
Neil J. Korman, Thierry Passeron, Kenneth B. Gordon, Yukari Okubo, Jerry Bagel, Howard Sofen, Richard B. Warren, Neal Bhatia, Lynda Spelman, Kevin Winthrop, Lauren Hippeli, Renata M. Kisa, Subhashis Banerjee, Diamant Thaçi, Deucravacitinib in plaque psoriasis: 2-year laboratory results from the phase 3 POETYK PSO program , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference®
Mark G Lebwohl, Jeffrey Sugarman, David M Pariser, Jerry Bagel, Cynthia Trickett, Abby Jacobson, Robert Israel, Safety and Tolerability of Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% (HP/TAZ) Lotion in Patients With Moderate-to-Severe Plaque Psoriasis: Results From a 1-Year, Open-Label Study , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 5 (2020): September Issue & Poster Presentations (FCPANP20® Dermatology Conference)
Jerry Bagel, April Armstrong, Richard Warren, Kim Papp, Diamant Thaçi, Alan Menter, Jennifer Cather, Matthias Augustin, Lauren Hippeli, Carolin Daamen, Christopher Griffiths, Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: 52-week efficacy by prior treatment in the phase 3 POETYK PSO-1 trial , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 6 (2022): November Issue & Poster Presentations from FC22 Dermatology Conference®
Diamant Thaci, Alice Gottlieb, Kristian Reich, Jerry Bagel, Daniel Burge, Luke Peterson, Janice Drew, Catherine Arendt, Jolanta Weglowska, Certolizumab Pegol for the Treatment of Chronic Plaque Psoriasis: DLQI and WPAI Patient-Reported Outcomes from Two Ongoing Phase 3, Multicenter, Randomized, Placebo-Controlled Studies (CIMPASI-1 and CIMPASI-2) , SKIN The Journal of Cutaneous Medicine: Vol. 1 (2017): Supplemental Issue: Scientific Posters Presented at 2017 Fall Clinical Dermatology Conference®-Las Vegas
Linda Stein Gold, Paul Yamauchi, David Pariser, Zhenyi Xu, Marie L Osterdal, Jerry Bagel, Treatment with Fixed Combination Calcipotriol 50 ug/g and Betamethasone Dipropionate 0.5 mg/g Foam Provides Rapid and Significant Itch Relief in Patients with Psoriasis , SKIN The Journal of Cutaneous Medicine: Vol. 2 (2018): Supplemental Issue: Scientific Posters Presented at 2018 Winter Clinical Dermatology Conference®-Hawaii
Brian S Kim, Robert Bissonnette, Kristine Nograles, Catherine Munera, Nilam Shah, Alia Jebara, Joshua Cirulli, Joana Goncalves, Mark Lebwohl, A Phase 2 Study of Oral Difelikefalin for Moderate-to-Severe Pruritus in Subjects With Notalgia Paresthetica (KOMFORT) , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 6 (2022): November Issue & Poster Presentations from FC22 Dermatology Conference®

<< < 1 2 3 4 > >>

Main Article Content

Keywords

Abstract

Article Sidebar

Article Details

Similar Articles

Most read articles by the same author(s)